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The donor blood supply of any country is a limited and carefully 
regulated resource. With only 1% of South Africans being active 
blood donors, an evidence-informed approach to blood transfusion 
helps to ensure that blood products are given to individuals who may 
derive benefit from their administration.[1] While blood transfusion 
is relatively safe, the potential for serious adverse events should 
be considered whenever a transfusion is ordered (Table 1). The 
annual Serious Hazards of Transfusion (SHOT) report details a 
risk of serious harm associated with transfusion as ~1 in 21 000 
and a risk of death as 1 in 117 000 components issued in the UK.[2] 
Blood transfusion should ideally be prescribed in the clinical setting 
where evidence supports efficacy, while balancing potential harm. 
Moreover, the indications for transfusion should be recognised 
promptly to reduce the sequelae of transfusion delays. Multiple 
trials, reviews and guidelines serve to inform appropriate transfusion 
thresholds in commonly encountered clinical contexts. 
Red blood cell transfusion 
What is the ideal red blood cell transfusion threshold? 
The default red blood cell transfusion (haemoglobin (Hb)) threshold 
had been 10.0 g/dL for >40 years, until a landmark clinical trial 
demonstrated that this liberal transfusion practice was largely 
unnecessary in the setting of critical care.[3] Clinical trials have 
likewise demonstrated the safety of a restrictive transfusion strategy 
in a variety of clinical settings. Despite these trials, the ‘optimal’ red 
cell transfusion threshold is unknown and reflects our rudimentary 
understanding of short- and long-term physiological adaptations to 
anaemia and an individual’s dynamic oxygen delivery needs. Despite 
these limitations, current transfusion thresholds identified through 
clinical trials provide a framework with which to approach patients. 
Non-bleeding hospitalised adult patients
The Transfusion Requirements in Critical Care (TRICC)  trial 
randomised non-bleeding euvolaemic critically ill patients to a 
‘restrictive’ red cell transfusion strategy (threshold of 7.0 g/dL) v. a 
‘liberal’ transfusion strategy (threshold of 10.0 g/dL).[3] This landmark 
trial published in 1999 showed for the first time that a restrictive 
transfusion strategy was safe and may even be beneficial in specific 
patient populations. A restrictive transfusion threshold resulted in a 
54% decrease in the number of red cell transfusions administered. 
Furthermore, 33% of patients in the restrictive arm were not transfused 
compared with 0% of the liberal arm. Subsequently, studies have been 
conducted in various patient populations, including orthopaedic 
and cardiac surgery, sepsis and haematopoietic cell transplantation 
(HCT). A Cochrane systematic review and meta-analysis recently 
evaluated clinical outcomes associated with restrictive (7.0 - 9.0 g/dL) 
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Table 1. Selected risks associated with blood product 
transfusion[17]
Risk* Blood product transfusion
1 in 13 Red cell sensitisation (increased risk 
for haemolytic transfusion reaction and 
haemolytic disease of the newborn)
1 in 20 Febrile non-haemolytic transfusion 
reaction per pool of platelets
1 in 100 Transfusion-associated circulatory 
overload
1 in 100 Urticaria
1 in 300 Febrile non-haemolytic transfusion 
reaction per red blood cell unit 
transfused
1 in 7 000 Delayed haemolytic transfusion reaction
1 in 10 000 Transfusion-related acute lung injury
1 in 40 000 Serious allergic reaction 
1 in 13 000 000 Hepatitis C virus infection
1 in 7 500 000 Hepatitis B virus infection
1 in 21 000 000 HIV infection
*Risk estimates are likely to have wide confidence intervals.
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v. liberal (10.0 g/dL) transfusion thresholds in 12 587 hospitalised 
patients enrolled in 31 randomised trials.[4] Restrictive transfusion 
strategies reduced the relative risk of receiving a blood transfusion 
by 43% and did not significantly impact relevant clinical outcomes. 
Uncertainty remains surrounding the optimal transfusion threshold 
in acute coronary syndromes (ACS) and traumatic brain injury 
(TBI); both are being evaluated in ongoing clinical trials (Myocardial 
Ischemia and Transfusion (MINT) trial for ACS (NCT02981407), 
and the HEMOglobin Transfusion Threshold in Traumatic brain 
Injury OptimizatioN (HEMOTION) trial for TBI (NCT03260478)). 
Based on the data described above, a transfusion threshold of 
7.0 g/dL is recommended for haemodynamically stable non-bleeding 
hospitalised patients, including those who are critically ill (Table 2). 
Most professional guidelines recommend that blood transfusions be 
used in symptomatic anaemia (chest pain, orthostatic hypotension, 
tachycardia unresponsive to fluid resuscitation or congestive heart 
failure) provided the Hb is <10.0 g/dL.[4] Despite a lack of randomised 
clinical trial data to support the adoption of a higher threshold, 
the American Association of Blood Banks (AABB) recommends a 
transfusion threshold of 8.0 g/dL in patients undergoing orthopaedic 
or cardiac surgery, and for those with pre-existing cardiovascular 
disease.[5] The recently published Transfusion Requirements in 
Cardiac Surgery (TRICS) III trial, demonstrating non-inferiority 
of a restrictive transfusion threshold of 7.5 g/dL in cardiac surgery, 
corroborates that a lower threshold is well tolerated in cardiac surgery 
patients.[6] In the setting of ACS, society guidelines support variable 
transfusion thresholds of >8.0 - 10.0 g/dL, while we await randomised 
data to better inform transfusion decisions in this patient population 
(Table 2).[5,7]
Bleeding hospitalised adult patients
In a single, large randomised controlled trial (RCT) of patients with 
gastrointestinal (GI) bleeding, a restrictive transfusion threshold 
of 7.0 g/dL (v. 9.0 g/dL) was associated with fewer red cell units 
transfused, less re-bleeding and increased survival at 30 days.[4] As 
such, haemodynamically stable patients with GI bleeding should 
be managed with a transfusion threshold of 7.0 g/dL (Table 2). In 
the context of massive transfusion protocols (MTPs) designed to 
provide optimal red blood cell (RBC):plasma:platelet ratios, the 
ideal transfusion threshold in massive transfusion is unknown. In 
the absence of randomised trials, maintaining a nadir Hb >8.0 g/dL 
is pragmatic; however, transfusion decisions should consider the 
clinical context and be modified by laboratory testing. 
Ambulatory patients with chronic transfusion requirements
There are limited randomised clinical trial data to guide outpatient 
transfusion thresholds. Two ongoing prospective pilot studies 
(NCT 02099669; ISRCTN 26088319) are evaluating optimal 
transfusion thresholds in myelodysplastic syndrome (MDS). These 
studies will evaluate the impact of liberal (Hb target >11.0 g/dL) v. 
restrictive (Hb target >8.5 g/dL) transfusion strategies on quality of 
life. Given the established safety of restrictive transfusion strategies 
in critically ill and hospitalised patients, and with the added concerns 
for increased risks of allo-immunisation and iron overload due to 
chronic transfusion, consensus recommendations suggest a restrictive 
transfusion threshold (typically 8.0 - 9.0 g/dL) in most ambulatory 
patients with acquired marrow failure syndromes (Table 2). 
Platelet transfusion 
Should platelets be transfused prophylactically, and at 
what platelet count threshold?
Similar to RBC transfusion decisions, the appropriateness of platelet 
transfusion must be considered in each specific clinical setting. 
Prophylactic transfusion strategies (i.e. transfusion at a pre-specified 
platelet count threshold to reduce the risk of bleeding) are important 
in the supportive care of many patients, but evolving evidence 
suggests that therapeutic transfusion strategies (i.e. at the first sign of 
bleeding) may be appropriate in specific clinical settings. 
Therapy-induced reversible myelosuppression
Prophylactic platelet transfusion strategies at platelet count thresholds 
of <10 × 109/L in patients with haematological malignancies who have 
therapy-related thrombocytopenia have been shown to primarily 
reduce the risk of World Health Organization (WHO) grade 2 
bleeding (Tables 3 and 4).[8] These results have been extrapolated 
to formulate recommendations in other settings of therapy-related 
hypoproliferative marrow states.[9-11] It is also recommended that 
prophylactic platelet transfusion (threshold of <10 × 109/L) be 
used for patients undergoing allogeneic HCT.[8] In the setting of 
autologous HCT, subgroup analysis of two RCTs demonstrates 
that therapeutic (compared with prophylactic) platelet transfusion 
strategies reduce platelet transfusions without impacting rates of 





recommendation Quality of evidence
Non-bleeding hospitalised patients
Haemodynamically stable (including critically ill*) 7.0 Strong Moderate
Haematopoietic cell transplant 7.0 Strong Moderate
Cardiac surgery (postoperatively) 7.5 Strong Moderate
Non-cardiac surgery† 8.0 Weak Low
Pre-existing cardiovascular disease 8.0 Weak Low
Acute coronary syndrome 8.0 - 10.0 Weak Very low
Traumatic brain injury 8.0 - 10.0 Weak Very low
Bleeding hospitalised patients
Haemodynamically stable gastrointestinal bleeding 7.0 Strong Moderate
Ambulatory patients 
Acquired marrow failure‡ 8.0 - 9.0 Weak Very low
Chemotherapy-induced marrow suppression 8.0 - 9.0 Weak Very low
*Admitted to an intensive care unit euvolaemic after initial resuscitation without evidence of ongoing blood loss.
†Evidence predominantly from orthopaedic surgery. 
‡Examples: myelodysplastic syndrome, myelofibrosis. 
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major bleeding (WHO grade 3 or 4 bleeding; Table 3). Given these 
data, several society guidelines currently suggest a therapeutic 
platelet transfusion strategy for patients undergoing autologous HCT 
(Table 4).[9,11] This approach requires inpatient-based monitoring 
with platelet transfusion at the first sign of clinically significant 
bleeding (WHO grade 2 or higher bleeding). As the aforementioned 
clinical trials have demonstrated that many of these patients continue 
to experience bleeding complications despite platelet transfusion, 
Table 3. Summary of the modified WHO bleeding scale[16]
WHO bleeding grade Examples
1 • Oropharyngeal bleeding ≤30 min in 24 h
• Epistaxis ≤30 min in previous 24 h
• Petechiae of oral mucosa or skin
• Purpura ≤2.5 cm in diameter
• Spontaneous haematoma in soft tissue or muscle
• Positive stool occult blood test
• Microscopic haematuria or haemoglobinuria
• Abnormal vaginal bleeding (spotting)
2 • Epistaxis >30 min in 24 h




• Gross (visible) haematuria
• Abnormal vaginal bleeding (more than spotting)
• Haemoptysis
• Visible blood in body cavity fluid
• Retinal bleeding without visual impairment
• Bleeding at invasive sites
3 • Bleeding requiring red blood cell transfusion over routine transfusion needs
• Bleeding associated with moderate haemodynamic instability
4 • Bleeding associated with severe haemodynamic instability
• Fatal bleeding
• CNS bleeding on imaging study with or without dysfunction
WHO = World Health Organization; CNS = central nervous system. 
Table 4. Prophylactic platelet transfusion thresholds*[9-11,15]





Treatment-related marrow suppression† <10 × 109/L Strong Moderate
Autologous haematopoietic cell transplantation Not recommended Weak Moderate
Chronic irreversible marrow failure‡ Not routinely required Weak Low
Critical illness <10 × 109/L Weak Low
Immune thrombocytopenia Not recommended Strong Low
Thrombotic thrombocytopenic purpura§ Contraindicated Strong Low
Prior to bone marrow biopsy Not routinely required Weak Low
Prior to paracentesis Not routinely required Weak Low
Prior to bronchoscopy with lavage <20 × 109/L Weak Low
Prior to chest tube insertion or thoracentesis <50 × 109/L Weak Low
Prior to elective central venous catheter¶ <20 × 109/L Weak Low
Prior to elective diagnostic lumbar puncture <50 × 109/L Weak Very low
Prior to urgent diagnostic lumbar puncture <20 × 109/L Weak Very low
Prior to major elective surgery (excluding neurosurgery) <50 × 109/L Weak Very low
Prior to neurosurgery <100 × 109/L Weak Low
Traumatic brain injury/intracranial haemorrhage <100 × 109/L Weak Low
Prior to insertion of an intraventricular drain <100 × 109/L Weak Low
*May be modified by individual patient factors that may increase bleeding risk, including comorbidities, use of antiplatelet/anticoagulants and clinical status.  
† Reversible bone marrow suppression (i.e. chemotherapy induced), including allogeneic haematopoietic cell transplantation, but not including inpatient autologous haematopoietic cell 
transplantation.
‡ Consider prophylaxis for patients with recurrent bleeding (World Health Organization grade 2 or higher[19]) and for those who are potential candidates for allogeneic haematopoietic cell 
transplantation.
§Platelet transfusions should only be used for life-threatening bleeding. 
¶ Inserted with bedside ultrasound and by experienced personnel. Avoid non-compressible vessels if platelets are <50 × 109/L. Choosing a compressible site is preferable to a prophylactic platelet 
transfusion.
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two ongoing clinical trials, TRial  to EvaluAte Tranexamic Acid 
Therapy in Thrombocytopenia (TREATT; NCT03136445) and 
Platelet Transfusion Requirements in Hematopoietic Transplantation 
(PATH; NCT02650791), evaluate the prophylactic use of tranexamic 
acid to prevent bleeding in patients with severe thrombocytopenia 
and haematological malignancies. 
Critically ill patients
Despite a lack of high-quality prospective data, prophylactic platelet 
transfusions at platelet thresholds of <10 × 109/L are recommended in 
the setting of critical illness with reversible marrow failure (Table 4).[9] 
Irreversible bone marrow failure (congenital or acquired)
A recent systematic review identified one small RCT (N=9) of 
therapeutic platelet transfusion strategies in MDS that was terminated 
early due to poor recruitment.[12] The paucity of data to inform 
decision-making, highlights the need for trials in this clinical context. 
A single retrospective study in severe aplastic anaemia evaluated 
outcomes associated with a prophylactic transfusion strategy (platelet 
threshold of ≤5 × 109/L). All deaths from haemorrhage were associated 
with preceding platelet alloimmunisation or palliation, and only three 
episodes of non-fatal major bleeding occurred.[13] Due to the risks of 
platelet alloimmunisation, and the economic burden associated with 
a chronic transfusion programme, several international guidelines 
recommend a therapeutic transfusion strategy unless there is evidence 
of recurrent bleeding (WHO grade 2 or higher (Tables 3 and 4)).[9,11] 
A caveat to this would be for potential candidates of allogeneic HCT, 
where a prophylactic transfusion strategy (platelet threshold of 
<10 × 109/L) is reasonable. 
Immune thrombocytopenia and thrombotic thrombo- 
cytopenic purpura
Prophylactic transfusion strategies are not recommended in the 
routine management of immune thrombocytopenia (ITP) owing to 
the ineffectiveness of platelet transfusion in this setting, as well as 
the potential of exacerbating the underlying prothrombotic disease 
state. In ITP, platelet transfusion should only be given therapeutically 
in serious bleeding situations or prior to urgent surgical/procedural 
interventions, perhaps also with the co-administration of intravenous 
immunoglobulin to reduce platelet consumption. In the absence of life-
threatening bleeding, prophylactic platelet transfusions are likewise 
contraindicated in the setting of thrombotic thrombocytopenic 
purpura (TTP), where studies have indicated an increase in mortality 
associated with platelet transfusions.[9] 
Before procedures or surgery
The need for prophylactic transfusion strategies prior to surgery or 
procedures has not been sufficiently evaluated in RCTs.[14] Existing 
recommendations are derived from observational studies that 
describe clinical outcomes following platelet transfusion for specific 
platelet thresholds (Table 3).[15] 
What is the appropriate dose of prophylactic platelet 
transfusion?
A large clinical trial (N=1 272), the Prophylactic Platelet Dose 
(PLADO) trial, demonstrated that in patients with hypoproliferative 
marrow disorders, low-dose platelet transfusions prescribed 
prophylactically at platelet concentrations of <10 × 109/L were as 
effective as higher doses of platelets in preventing WHO grade 2 
or higher bleeding complications.[16] Accordingly, in non-bleeding 
patients, if a prophylactic platelet transfusion strategy is adopted, 
guidelines recommend transfusion with one adult dose of plate lets.[9,10] In 
the absence of consumption or destruction, each platelet dose should 
increase an adult patient’s platelet count by 15 - 25 × 109/L when 
measured at 1 hour. If a platelet increment of <10 × 109/L is achieved 
post-transfusion on more than one occasion, platelet refractoriness 
and the need for consultation with transfusion medicine experts are 
suggested.[17] 
Are transfusion ‘thresholds’ the best determinant of the 
need for transfusion?
While the adoption of specific transfusion thresholds can prevent over-
utilisation of blood products, it is equally important to acknowledge 
the limitations of ‘threshold’ decisions in clinical practice. Clinical 
scenarios are varied and require a nuanced interpretation of the 
risks and benefits of transfusion. This notion is highlighted in the 
setting of anaemia of chronic disease. This condition is often viewed 
as deleterious due to the assumed reduction in oxygen delivery to 
tissues, as well as the association of anaemia with poor prognosis 
in many clinical disorders, but these notions are debatable. Firstly, 
the ability of the body to compensate for the often mild to moderate 
anaemia (Hb >8.0 g/dL) observed in chronic disease through both 
increased oxygen unloading and increased oxygen tissue extraction is 
typically sufficient to maintain adequate oxygen delivery.[18] Secondly, 
while anaemia is associated with increased mortality in many 
diseases, it is not proof of causation. Several studies have shown that 
when disease severity and inflammation are accounted for, anaemia 
of chronic disease is no longer prognostic for mortality. Moreover, 
the development of anaemia in response to systemic disease is 
evolutionally conserved in animals with closed circulatory systems 
and suggests an adaptive response.[18] As such, not all anaemias are 
equal, and an understanding of the aetiology and physiological impact 
of anaemia is fundamental in determining transfusion thresholds 
for individual patients. Likewise, the decision to transfuse platelets 
based solely on a number may fail to consider the presence of platelet 
dysfunction (either congenital or acquired), concomitant coagulopathy, 
and the potential consequence of bleeding, should it occur. 
Conclusions
The transfusion of blood products is one of the most routine 
interventions in healthcare. As the provision of blood products relies 
on a limited resource, transfusion practices need to be carefully 
scrutinised. A one-size-fits-all approach in clinical practice has 
appropriately fallen by the wayside, and, as this review demonstrates, 
the decision to transfuse blood products is no exception. While 
the referenced transfusion thresholds serve as a general guide that 
reflects the best available data, each patient, their comorbidities, 
preferences, as well as the clinical settings, should be considered prior 
to the prescription of a blood product transfusion. 
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